Novo Nordisk Gains CHMP Positive Opinion for Oral Wegovy as First EU GLP-1 Obesity Pill

Novo Nordisk's CHMP positive opinion for once-daily oral semaglutide 25 mg (Wegovy® pill) sets a manufacturing and supply-chain clock ticking: the company must scale solid-dose production for EU markets while sustaining injectable Wegovy® output, with a planned ex-US launch window opening in the second half of 2026.

The Committee for Medicinal Products for Human Use (CHMP) adopted its positive opinion on 22 May 2026, recommending marketing authorisation for Wegovy® pill to reduce excess body weight and maintain long-term weight reduction in adults with obesity or overweight and at least one weight-related comorbidity. The opinion incorporates SELECT cardiovascular outcomes data, placing MACE risk-reduction language directly in the proposed EU label, a regulatory distinction that broadens the prescribing population and, by extension, the demand signal manufacturers must plan against.

Efficacy data from the OASIS 4 phase 3b trial underpins the submission: oral semaglutide 25 mg delivered 16.6% mean weight loss over 64 weeks in 307 adults, comparable to injectable Wegovy® 2.4 mg, with one in three participants achieving 20% or greater weight loss. The label carries no drug-drug restrictions with concomitant medications, removing a formulary barrier that has complicated GLP-1 uptake in polypharmacy patient populations.

For QA directors and regulatory affairs leads, the absence of drug-drug interaction restrictions reflects a clean ICH Q8-aligned formulation profile, but it also raises post-approval commitments around pharmacovigilance and real-world safety surveillance across a broader concomitant-medication landscape. Semaglutide already carries more than 50 million patient-years of real-world safety data, which supported the tolerability assessment in OASIS 4.

The US precedent adds operational weight to the EU timeline. More than one million Americans initiated Wegovy® pill within the first four months of FDA-authorised launch, a volume uptake rate that plant heads and CMO partners will need to model against EU market entry projections. Solid-dose GLP-1 manufacturing at commercial scale introduces different process validation requirements than the prefilled-pen injectable supply chain Novo Nordisk has been managing under sustained demand pressure.

The European Commission's formal marketing authorisation decision, which typically follows a CHMP positive opinion within approximately two months, will mark the point at which batch release timelines, serialisation obligations under the Falsified Medicines Directive, and country-level pricing and reimbursement negotiations converge into a single launch-readiness checkpoint.

Source: Novo Nordisk A/S via GlobeNewswire, 22 May 2026.